Traditional Chinese medicine combined with pulmonary drug delivery system and idiopathic pulmonary fibrosis: Rationale and therapeutic potential - 19/12/20
pages | 11 |
Iconographies | 4 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | Pathogenesis and characteristics of idiopathic pulmonary fibrosis (IPF) are presented. |
• | The history and current situation of traditional Chinese medicine (TCM) in treating lung diseases are introduced. |
• | Therapeutic mechanisms of different TCM to treat IPF are summarized. |
• | Advantages and types of pulmonary drug delivery systems (PDDS) are emphasized. |
• | Combining TCM with PDDS is a potential strategy to treat IPF. |
Abstract |
Idiopathic pulmonary fibrosis (IPF) is a progressive pulmonary interstitial inflammatory disease of unknown etiology, and is also a sequela in severe patients with the Coronavirus Disease 2019 (COVID-19). Nintedanib and pirfenidone are the only two known drugs which are conditionally recommended for the treatment of IPF by the FDA. However, these drugs pose some adverse side effects such as nausea and diarrhoea during clinical applications. Therefore, it is of great value and significance to identify effective and safe therapeutic drugs to solve the clinical problems associated with intake of western medicine. As a unique medical treatment, Traditional Chinese Medicine (TCM) has gradually exerted its advantages in the treatment of IPF worldwide through a multi-level and multi-target approach. Further, to overcome the current clinical problems of oral and injectable intakes of TCM, pulmonary drug delivery system (PDDS) could be designed to reduce the systemic metabolism and adverse reactions of the drug and to improve the bioavailability of drugs. Through PubMed, Google Scholar, Web of Science, and CNKI, we retrieved articles published in related fields in recent years, and this paper has summarized twenty-seven Chinese compound prescriptions, ten single TCM, and ten active ingredients for effective prevention and treatment of IPF. We also introduce three kinds of inhaling PDDS, which supports further research of TCM combined with PDDS to treat IPF.
Le texte complet de cet article est disponible en PDF.Abbreviations : IPF, COVID-19, TCM, PDDS, TGF, α-SMA, HYP, TNF-α, INF-γ, Smad3, TIMP-1, ECM, Nrf2, NOX4, MAPK, PI3K, AKt, EMT, LPO, HSP90, VASH, HLF, CUR, MMP, QE, HELF, SphK1, S1P, GA, PDGF, FGF, ASV, Col III, LN, HA, FOXO3a, SAB, JNK, ACE-2, ANG-(1-7), IL-6, HSP-47, MDA, GSH, ERK, MDI, PMDI, NEB, DPI
Keywords : Traditional Chinese medicine, Pulmonary drug delivery system, COVID-19, Idiopathic pulmonary fibrosis
Plan
Vol 133
Article 111072- janvier 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?